Insider buying last 90 days
No open-market insider purchases were filed for BIIB in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every BIIB insider filing, plotted on the chart in Gekko.Open BIIB in Gekko
NASDAQ: BIIB
Biogen (BIIB) Stock Analysis & Forecast
Nov 4 close
$254.46+5.53 (+2.2%)
Gekko Brief
AI summaryNov 4 closeBiogen's week reflects strong third-quarter results, with total revenue growing 11% year-over-year, aided by the Appellis acquisition, and the growth portfolio reaching $1.26 billion, up 50% year-over-year. SYFOVRE and Empaveli combined reached $243 million, a 37% year-over-year increase, on roughly a $1 billion annual run rate, while Guggenheim raised its price target to $300 from $280, maintaining a Buy rating. New Alzheimer's data and research spending tied to Leqembi have also drawn investor scrutiny, even as the company swung to a loss in the quarter.
The stock closed at $254.46, up 2.2%, sitting above both its 50-day average of $229.01 and its 200-day average of $202.45, with the 50-day above the 200-day. The GekkoIndex reads 48.3, placing it in the Neutral zone. Gekko Fair Value stands at $344.45, leaving price 26.1% below that level.
The next earnings date falls on 5 February 2027, 92 days out, beyond a typical 20-trading-day hold. Over the last 90 days, Congress recorded 1 buy and 0 sells, and the last 30 days show 2 unusual options signals, with call premium of $1,120,089 against put premium of $770,595. Seasonally, the next 20 trading days have averaged -1.8% over 5 years, rising in 2 of them, a pattern worth noting alongside the gap to Gekko Fair Value.
Written by AI from the Nov 4, 2026 close and checked automatically against the figures on this page.
Biogen price vs fair value
Close $254.46200-day averageGekko Fair Value $344.45
Biogen quick facts
- Market cap
- $37.61B
- P/E ratio
- 107.8
- Forward P/E
- 15.6
- EPS, TTM
- $2.31
- Revenue, TTM
- $10.30B
- Profit margin
- 3.4%
- Dividend yield
- —
- Beta
- 0.09
- Volume
- 1.21M avg 1.34M
- 1-year return
- +68.0%
- Typical daily move
- ±3.2%
- Typical 20-day move
- ±5.1%
- 50-day average
- $229.01
- 200-day average
- $202.45
- Next earnings
- Feb 5 before open
- Shares outstanding
- 147.8M
Biogen swing-trade checklist
Biogen scores 4 supportive, 1 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed1 headwind
- Trendsupportive
Above 50 and 200-day
Close $254.46 is above the 50-day ($229.01) and 200-day ($202.45) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
48.3, Neutral
Reading 48.3 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
26.1% below
Price is 26.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: Congress 1 buy / 0 sales. Last 30 days: 2 unusual options signals.
See smart money - Earnings risksupportive
Reports in 92 days
Next report Feb 5, 2027, 92 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−1.8% on average
From this point in the calendar, the next 20 trading days averaged −1.8% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Biogen stock chart and price history
Biogen closed at $254.46 on Nov 4, 2026, +68.0% over the past year, inside a 52-week range of $148.51 to $258.78.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +14.2%
- 3 months
- +23.4%
- 6 months
- +33.4%
- 1 year
- +68.0%
The full BIIB chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BIIB in Gekko
Follow Biogen through every session
Put BIIB on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track BIIB in GekkoFree for 7 days. No credit card required.
About Biogen
Biogen works in medicine for the brain and nervous system, focused on discovering, developing and manufacturing treatments for neurological and neurodegenerative disease. It is best known for its multiple sclerosis medicines, among them TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA, alongside OCREVUS for relapsing and primary progressive MS and ADUHELM for Alzheimer's disease.
Beyond neurology, the company sells SPINRAZA for spinal muscular atrophy and FUMADERM for plaque psoriasis, along with cancer and immune therapies such as RITUXAN, RITUXAN HYCELA and GAZYVA, used against lymphoma, leukemia, rheumatoid arthritis and related conditions. It also produces biosimilar versions of established biologics, including BENEPALI, IMRALDI and FLIXABI. Its pipeline spans investigational compounds for MS, Alzheimer's and dementia, neuromuscular and movement disorders, psychiatric conditions, immunology, acute neurological events and neuropathic pain, together with additional biosimilars in development.
Biogen trades on the NASDAQ under the ticker BIIB.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- biogen.com
Biogen GekkoIndex: the smart money zone
Biogen’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 48.3, in the Neutral zone, down 0.6 points over five sessions.
48.3Neutral
Down 0.6 points over five sessions.
Reading for Nov 4, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 66 | +0.2% | −1.9% | ||
| Accumulation | 215 | −0.5% | −1.2% | ||
| Neutral (current zone) | 387 | +0.4% | +1.5% | ||
| Distribution | 27 | −0.1% | −2.0% | ||
| Selling | 2 | Too few readings yet | |||
Average BIIB share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.0% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the BIIB price, zone by zone.Track BIIB in Gekko
Is Biogen stock overvalued? Gekko Fair Value
Biogen trades 26.1% below Gekko Fair Value of $344.45, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Biogen shares are worth, recalculated every trading day.
$344.45
Gekko Fair Value, Nov 4, 2026
26.1% Undervalued
At the end of Aug 2026 the price was 42.9% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open BIIB in Gekko
Biogen insider and Congress trading
No open-market insider purchases were filed for Biogen, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
1trade disclosed: 1 purchase and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Ro Khanna House, CA, purchase | $1,001 - $15,000 | Oct 9 traded Sep 4 |
From congressional disclosures, which report amounts as ranges.
Buybacks
Biogen has been buying back its own shares.
- Bought back, quarter ended Sep 30, 2022
- $250.0M
- As a share of market cap
- 0.66%
From company filings.
Unusual options activity last 30 days
2signals, 59% of the flagged premium in calls.
Latest: Bearish flow on Oct 24, $791K in unusual premium.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds BIIB.
0added1opened0trimmed1sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko
Biogen earnings: next date and track record
Biogen reports on Feb 5, 2027, before the open (92 days away), and beat the EPS estimate in 8 of its last 8 reports.
Next earnings report
Feb 5, 2027
Expected before the open, 92 days away
- EPS estimate
- $2.85
- Revenue estimate
- $2.61B
8 of 8reports beat the EPS estimate
±2.7%average move across the report
6 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Oct 28, 2026 AI summary
- What they said
- Biogen reported a strong Q3 with total revenue growing 11% year-over-year, significantly aided by the Appellis acquisition. SYFOVRE and Empaveli combined reached $243M (37% YoY growth), on a ~$1B annual run rate. The growth portfolio hit $1.26B, up 50% YoY, representing nearly two-thirds of core pharma revenue. Cost synergies from Appellis integration are tracking ahead of schedule, targeting $250M run rate by end of 2027.
- Guidance
- Biogen expects to return to top-line growth in 2026. Acquisition dilution is now projected to be minimal at the operating level, with most dilution stemming from financing costs. First pipeline data readouts are expected within weeks.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 28, 2026 | $2.62 est $1.99 | $2.80B est $2.63B | −1.2% |
| Jul 29, 2026 | $3.60 est $3.04 | $2.74B est $2.46B | +1.1% |
| Apr 29, 2026 | $3.57 est $2.89 | $2.48B est $2.29B | +3.2% |
| Feb 6, 2026 | $1.99 est $1.63 | $2.28B est $2.20B | +4.6% |
| Oct 30, 2025 | $4.81 est $3.88 | $2.45B est $2.34B | +4.3% |
| Jul 31, 2025 | $5.47 est $3.90 | $2.65B est $2.33B | +4.2% |
| May 1, 2025 | $3.02 est $2.90 | $2.43B est $2.23B | +2.0% |
| Feb 12, 2025 | $3.44 est $3.36 | $2.45B est $2.41B | −0.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Biogen stock forecast and analyst price targets
Analysts’ average 12-month price target for Biogen is $264.23, +3.8% from the last close, from 26 firms rating the stock in the last 90 days.
$264.23consensus 12-month target, +3.8% from the last close
Now $254.46Avg $264.23
Low $175High $325
Each firm’s latest rating in the last 90 days: 26 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 2 | Guggenheim | $300 | +17.9% |
| Nov 2 | H.C. Wainwright | $270 | +6.1% |
| Nov 2 | BMO Capital | $250 | −1.8% |
| Oct 29 | Bank of America Securities | $257 | +1.0% |
| Oct 29 | TD Cowen | $260 | +2.2% |
+1.5%average 20-day move after past Neutral readings
−1.8%average move over the next 20 trading days in the last 5 years
±3.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Biogen seasonality: the next 20 trading days
Over the next 20 trading days from Nov 4, Biogen averaged −1.8% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −1.2% | 2 of 5 |
| Next 10 trading days | −1.1% | 2 of 5 |
| Next 15 trading days | −1.0% | 2 of 5 |
| Next 20 trading days | −1.8% | 2 of 5 |
| Next 30 trading days | −2.4% | 3 of 5 |
For scale, BIIB’s typical 20-trading-day move in either direction is about 5.1%.
Biogen market cap and key statistics
Biogen’s market cap is $37.61B, with a P/E ratio of 107.8 and revenue of $10.30B over the last twelve months.
Valuation
- Market cap
- $37.61B
- P/E ratio
- 107.8
- Forward P/E
- 15.6
- EPS, TTM
- $2.31
- Gekko Fair Value
- $344.45
Trading
- Volume
- 1.21M
- Avg volume, 20 days
- 1.34M
- 52-week high
- $258.78
- 52-week low
- $148.51
- Shares outstanding
- 147.8M
Financials
- Revenue, TTM
- $10.30B
- Profit margin
- 3.4%
- Return on equity
- 1.9%
- Quarterly earnings growth, YoY
- −84.8%
Risk and income
- Beta
- 0.09
- Typical daily move
- ±3.2%
- Typical 20-day move
- ±5.1%
Biogen stock news this week
Coverage of Biogen this week reads neutral: 4 positive, 7 neutral and 1 negative headlines.
- Biogen Inc (IDP.HA) Seasonal returns chartYahoo Finance Singapore, Nov 4
- Form 4 Biogen Inc: Jane Grogan (Head of Research) For: 30 October By Investing.comInvesting.com South Africa, Nov 3
- Biogen's Jane Grogan Executes 695 RSU Conversion and Tax Withholding on October 30, 2026Kalkine Media, Nov 3
- Form 4 Biogen Inc: Jane Grogan (Head of Research) For: 30 OctoberInvesting.com Canada, Nov 3
- Research head acquires 695 Biogen (BIIB) shares through a stock award conversion.Stock Titan, Nov 2
- Biogen Inc. stock underperforms Monday when compared to competitorsMarketWatch, Nov 2
Biogen peers
Biogen’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Distribution | 27.7% above |
| JNJJohnson & Johnson | Neutral | 1.7% below |
| ABBVAbbVie | Neutral | 26.5% above |
| MRKMerck | Neutral | 8.6% below |
| AZNAstraZeneca | Distribution | 34.1% below |
| PFEPfizer | Neutral | 4.1% below |
A peer links to its own page where one exists.
Biogen stock FAQ
What is Biogen’s market cap?
Biogen’s market cap is $37.61B at the Nov 4, 2026 close of $254.46, with 147.8M shares outstanding. The shares trade on a P/E ratio of 107.8.
What is the Biogen stock forecast?
The consensus analyst 12-month price target for Biogen is $264.23, +3.8% from the last close. Of the 26 firms that rated the stock in the last 90 days, 19 rate it a buy, 6 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
Is Biogen stock overvalued or undervalued?
On Gekko’s estimate Biogen is undervalued: the Nov 4, 2026 close of $254.46 is 26.1% below Gekko Fair Value of $344.45. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Biogen report earnings next?
Biogen is expected to report on Feb 5, 2027, before the market opens (92 days away). Analysts expect earnings of $2.85 per share on revenue of $2.61B. Biogen beat the earnings estimate in 8 of its last 8 reports, moving 2.7% on average across the report.
What is Biogen’s 52-week high and low?
Biogen’s 52-week high is $258.78 and its 52-week low is $148.51; it closed at $254.46 on Nov 4, 2026, +68.0% over the past year. Over the last five years the shares peaked at $319.76 on Jun 12, 2023.
Is Biogen stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (trend, fair value, smart money and earnings risk), 1 as mixed (gekkoindex) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in Biogen?
Gekko flagged 2 unusual options signals in Biogen over the last 30 days, with $1.12M of flagged premium in calls and $771K in puts. The latest, bearish flow, was on Oct 24, 2026 with $791K in unusual premium. The signal-by-signal table is in Gekko.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Biogen the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,461 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.